A class action accuses REGENXBIO and officers of securities violations for allegedly misleading statements about RGX-111 for Hurler syndrome; investors who bought between Feb 9, 2022 and Jan 27, 2026 may join; lead plaintiff deadline Apr 14, 2026.Abstract: This filing by Bronstein, Gewirtz & Grossman LLC alleges that REGENXBIO and its officers violated federal securities laws by making false and misleading statements about RGX-111 for Hurler syndrome. It invites investors who purchased REGENXBIO securities from February 9, 2022, to January 27, 2026, to join, with a lead plaintiff deadline of April 14, 2026.

NodeGuardian

2026-04-21 20:06:35

Abstract generation in progress

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and its officers, alleging violations of federal securities laws. The lawsuit claims that REGENXBIO made materially false and misleading statements regarding its RGX‑111 gene therapy for Hurler syndrome. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the case, with a lead plaintiff deadline of April 14, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
300.76K Popularity
#
Gate13thAnniversaryLive
760.16K Popularity
#
BitcoinBouncesBack
174.43K Popularity
#
USIranTalksProgress
880.39K Popularity
#
HKUnveilsNewCryptoRules
275.22K Popularity

Sitemap

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

BitcoinBouncesBack

USIranTalksProgress

HKUnveilsNewCryptoRules

Pin